Immunotherapy of melanoma

被引：43

作者：

Parmiani, G ^{[1
]}

Castelli, C ^{[1
]}

Rivoltini, L ^{[1
]}

Casati, C ^{[1
]}

Tully, GA ^{[1
]}

Novellino, L ^{[1
]}

Patuzzo, A ^{[1
]}

Tosi, D ^{[1
]}

Anichini, A ^{[1
]}

Santinami, M ^{[1
]}

机构：

[1] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy

来源：

SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 06期

关键词：

melanoma; antigens; vaccination; adoptive immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; COLONY-STIMULATING FACTOR; CD8(+) T-CELLS; PHASE-I TRIAL; HEAT-SHOCK-PROTEIN-70 PEPTIDE COMPLEXES; INCOMPLETE FREUNDS-ADJUVANT; BLOOD MONONUCLEAR-CELLS; PULSED DENDRITIC CELLS; HEAT-SHOCK PROTEINS; METASTATIC MELANOMA;

D O I：

10.1016/j.semcancer.2003.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：391 / 400

页数：10

共 79 条

[51] Pende D, 2002, CANCER RES, V62, P6178
[52] High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
Pittet, MJ
Valmori, D
Dunbar, PR
Speiser, DE
Liénard, D
Lejeune, F
Fleischhauer, K
Cerundolo, V
Cerottini, JC
Romero, P
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) : 705 - 715
[53] A listing of human tumor antigens recognized by T cells
Renkvist, N
Castelli, C
Robbins, PF
Parmiani, G
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (01) : 3 - 15
[54] Reynolds SR, 2003, CLIN CANCER RES, V9, P657
[55] Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma
Ridolfi, L
Ridolfi, R
Riccobon, A
De Paola, F
Petrini, M
Stefanelli, M
Flamini, E
Ravaioli, A
Verdecchia, GM
Trevisan, G
Amadori, D
[J]. JOURNAL OF IMMUNOTHERAPY, 2003, 26 (02): : 156 - 162
[56] Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells
Rivoltini, L
Castelli, C
Carrabba, M
Mazzaferro, V
Pilla, L
Huber, V
Coppa, J
Gallino, G
Scheibenbogen, C
Squarcina, P
Cova, A
Camerini, R
Lewis, JJ
Srivastava, PK
Parmiani, G
[J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (07) : 3467 - 3474
[57] Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
Rivoltini, L
Carrabba, M
Huber, V
Castelli, C
Novellino, L
Dalerba, P
Mortarini, R
Arancia, G
Anichini, A
Fais, S
Parmiani, G
[J]. IMMUNOLOGICAL REVIEWS, 2002, 188 : 97 - 113
[58] RIVOLTINI L, 1995, J IMMUNOL, V154, P2257
[59] Rosenberg SA, 1999, J IMMUNOL, V163, P1690
[60] Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, SA
Yang, JC
Schwartzentruber, DJ
Hwu, P
Marincola, FM
Topalian, SL
Restifo, NP
Dudley, ME
Schwarz, SL
Spiess, PJ
Wunderlich, JR
Parkhurst, MR
Kawakami, Y
Seipp, CA
Einhorn, JH
White, DE
[J]. NATURE MEDICINE, 1998, 4 (03) : 321 - 327

← 1 2 3 4 5 6 7 8 →